Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsFeatured Stories

Featured Stories

Hot information：
Top 10 Global CDMO Enterprises| The Meaning of IND, NDA and ANDA| Top 10 Global Clinical Research Organizations in 2021
Aug 08,2019
Biacore 8k Services
SPR, surface plasmon resonance, reveal the interaction between proteins and other biomolecules through physical optical effects, to help customers understand molecular functions and screen effective molecules. It can replace and is superior to tests such as WB/Elisa/CO-IP-/Pull-down/ChIP/EMSA/FRET/Yeast two-hybrid. Medicilon has an advanced instrument Biacore 8K and an experienced team to help you complete the SPRRead more
More
Biacore 8k Services
Jul 03,2019
There are great ways to fight tumors
In 2015, the 90-year-old former US President Carter unfortunately suffered from melanoma with brain metastases. After receiving comprehensive treatment including immunotherapy, the tumor in the brain miraculously disappeared. Against the background of the time, the emergence of this incident was like a ray of light in the dark, illuminating the dark road for people toRead more
More
There are great ways to fight tumors
Jun 07,2019
Medicilon helps ImmuneOnco Biopharma's target CD47 fusion protein drug to obtain NMPA clinical trial license
Recently, ImmuneOnco Biopharma, a partner of Shanghai Medicilon Inc., announced that its newly developed immune checkpoint inhibitor has been approved by the National Medical Products Administration (NMPA), which marks the beginning of a new phase of research on the first CD47 fusion protein drug in China. It is reported that ImmuneOnco Biopharma submitted the INDRead more
More
Medicilon helps ImmuneOnco Biopharma's target CD47 fusion protein drug to obtain NMPA clinical trial license
Apr 30,2019
The CRO Market is Expected to be Close to 100 Billion in 2020
As an important link in the R&D industry chain of pharmaceutical companies, the CRO industry has obtained important development opportunities and the scale of the industry has grown rapidly. China is the world's second largest drug-using country and the fastest growing economy in the global drug market. The national pharmaceutical policy is gradually clarified, theRead more
More
The CRO Market is Expected to be Close to 100 Billion in 2020
Feb 26,2019
Anti-Influenza Virus Drug-Oseltamivir Phosphate Passed the Consistency Evaluation
Oseltamivir phosphate is a kind of specific influenza virus neuraminidase inhibitor, and it is an effective way to treat influenza virus clinically. Recently, a Chinese pharmaceutical company’s oseltamivir phosphate capsule (75mg) passed the consistency evaluation for the first time, which enabled it to gain advantages in future market expansion and medical insurance payment. The supplementaryRead more
More
Feb 01,2019
Happy Chinese New Year from Medicilon!
Read more
More
Happy Chinese New Year from Medicilon!
Jan 07,2019
hERG IC50, better or worse?
According to literature statistics [1], the cardiotoxicity of anti-tumor drug treatment mainly includes 9 aspects: heart insufficiency and heart failure, coronary heart disease, heart valve disease, arrhythmia (especially prolonged QT interval), hypertension, thromboembolic Disease, peripheral vascular disease and stroke, pulmonary hypertension and pericardial complications. Among them, the side effects of prolonged QT interval have becomeRead more
More
Dec 30,2018
Top Ten Global CRO Companies
CRO (Contract Research Organization) is mainly engaged in the design and consultation of clinical trial protocols and case reports, as well as trial supervision, data management, statistical analysis and submission of systematic evaluation results. The global CRO market is still growing steadily. The current market size is about 40 billion U.S. dollars, with an averageRead more
More
Top Ten Global CRO Companies
Dec 21,2018
Research progress of highly selective mTOR inhibitors
PI3K/AKT/mTOR PI3K/AKT/mTOR is an important signaling pathway in cells, which is related to key regulators such as metabolism, cell growth, proliferation and survival in the body, and is over-activated in cancer and neurodegenerative diseases [1]. The specific process of its signaling pathway is as follows: PIP3 binds to the signaling proteins AKT and PDK1 inRead more
More
Research progress of highly selective mTOR inhibitors
Nov 30,2018
Improved Humanized Mice Enhance Vaccine Development
Every animal model of disease comes with its own unique set of drawbacks. Yet, scientists continually push to improve the quality of animal models to recapitulate the physiological and molecular signatures of disease states. For decades, researchers have turned to mice whose immune systems have been "humanized” to respond in a manner similar to humans.Read more
More
Improved Humanized Mice Enhance Vaccine Development
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->